- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01320280
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
Single-arm, Open-label, Single-center Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer After Failure of Treatment With Docetaxel or Ineligible for Treatment With Docetaxel
The purpose of this study is to find out what effects, good and/or bad, BIBW 2992 (Afatinib) has on patients and their advanced prostate cancer which does not respond to hormone or chemotherapy any more. Only patients with tumors which have an increased amounts of a protein called HER2 on their cell surface will be included.
BIBW 2992 (Afatinib) is a drug which in advanced clinical testing in lung and breast cancer.
Studieoversigt
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Hamburg, Tyskland, 20246
- University Medical Center Hamburg-Eppendorf
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients must provide written informed consent
- Age ≥ 18 years
- Patients must have histological proven, hormone-refractory prostate cancer
- Patients must have failed prior therapy with docetaxel or must be ineligible for treatment with docetaxel
- Patients must have ECOG performance status ≤ 2
- Patients must not have received any prior therapy targeting EGFR or HER2
- Patients must have adequate bone marrow, renal and hepatic function
- Patients must not have a history of severe heart disease
- Patients must not have had a myocardial infarction within the previous six months
- Patients must have normal left ventricular ejection fraction (LVEF ≥ normal limit of institution)
- Patients must not have symptomatic brain or leptomeningeal metastatic disease
- Patients must have recovered from previous treatment-related adverse effects to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) grade ≤ 1
Exclusion Criteria:
- Prior treatment with EGFR/HER2-targeted small molecules or antibodies, i.e. trastuzumab and/or lapatinib
- Known pre-existing interstitial lung disease
- Radiotherapy, chemotherapy, hormone therapy (with the exception of GnRH agonists), immunotherapy or surgery (other than biopsy) within 4 weeks prior to start of treatment with BIBW2992. GnRH-agonists are allowed at the discretion of the investigator.
- Active brain metastases (defined as stable for < 4 weeks and/or symptomatic and/or requiring changes of treatment with anticonvulsants or steroids within the past 4 weeks and/or leptomeningeal disease). Patients with known history of brain metastases should undergo a baseline brain image to ensure that the disease is stable.
- Any other current malignancy or malignancy diagnosed within the past five (5) years (other than non-melanomatous skin cancer).
- Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom, e.g. Crohn's disease, malabsorption or CTC grade ≥ 2 diarrhoea of any aetiology.
- History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation.
- Cardiac left ventricular function with resting ejection fraction of less than 50%.
- Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient's safety or interfere with the evaluation of the safety of the test drug.
- Absolute neutrophil count (ANC) < 1500 / mm³.
- Platelet count < 75,000 / mm³
- Calculated creatinine clearance < 60 ml / min (using Cockcroft-Gault formula for GFR estimate) or serum creatinine > 1.5 times upper limit of normal.
- Uncontrolled hypercalcemia
- Patients unable to comply with the protocol.
- Known hepatitis B infection, known hepatitis C infection or known HIV carrier.
- Known or suspected active drug or alcohol abuse.
- Requirement for treatment with any of the prohibited concomitant medications
- Any contraindications for therapy with BIBW 2992.
- Known hypersensitivity to BIBW 2992.
- Use of any investigational drug within 4 weeks of start of treatment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: BIBW 2992 (Afatinib)
BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
|
50 mg BIBW 2992 (Afatinib) tablets daily continuously
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective PSA responses according to Bubley criteria
Tidsramme: every two months
|
Bubley criteria see Bubley GJ, et al.
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
J Clin Oncol 1999; 17: 3461-3467
|
every two months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Tidsramme: every 2 months
|
every 2 months
|
|
Duration of PSA-response (Bubley criteria) or objective responses
Tidsramme: every 2 months
|
every 2 months
|
|
Safety
Tidsramme: every 4 weeks
|
Description AEs according to CTC criteria
|
every 4 weeks
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Walter Fiedler, M.D:, Universitätsklinikum Hamburg-Eppendorf
Publikationer og nyttige links
Generelle publikationer
- Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2.
- Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brummendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res. 2010 Mar 1;16(5):1553-60. doi: 10.1158/1078-0432.CCR-09-2546. Epub 2010 Feb 23.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 1200.138
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Ildfast kræft
-
Nantes University HospitalTrukket tilbageCD22+ Relapsed/Refractory B-ALLFrankrig
-
European Society for Blood and Marrow TransplantationMallinckrodtAfsluttetSteroid Refractory GVHDSpanien, Det Forenede Kongerige, Sverige, Italien, Israel, Frankrig, Danmark, Tyskland, Polen, Kalkun, Rumænien, Belgien, Grækenland, Den Russiske Føderation
-
Samsung Medical CenterAfsluttetHER2-positiv Refractory Advanced CancerKorea, Republikken
-
Shanghai Pudong HospitalUTC Therapeutics Inc.Trukket tilbageMesothelin-positive Advanced Refractory Solid TumorsKina
-
Agenus Inc.AfsluttetAvancerede solide kræftformer | Advanced Solid Cancers Refractory to PD-1Forenede Stater
-
ElsaLys BiotechIkke rekrutterer endnu
-
MaaT PharmaRekrutteringSteroid Refractory GVHD | Tarm GVHDFrankrig
-
Yi-Lun WangAfsluttetSteroid Refractory GVHDTaiwan
-
Columbia UniversityIncyte CorporationAfsluttetGraft vs værtssygdom | Steroid Refractory GVHDForenede Stater
-
Fujian Cancer HospitalIkke rekrutterer endnuHawthorn Red Kombineret Refractory Cancer Smerter
Kliniske forsøg med BIBW 2992 (Afatinib)
-
Centre Leon BerardBoehringer IngelheimAfsluttetPlanocellulært karcinom i hoved og halsFrankrig
-
Boehringer IngelheimAfsluttetBrystneoplasmerForenede Stater, Det Forenede Kongerige
-
Boehringer IngelheimAfsluttet
-
Boehringer IngelheimAfsluttetGliomForenede Stater, Canada
-
Medical University of South CarolinaBoehringer IngelheimTrukket tilbageLungekræftForenede Stater
-
Boehringer IngelheimAfsluttetKarcinom, ikke-småcellet lungeKorea, Republikken
-
Boehringer IngelheimAfsluttet
-
University of ChicagoNational Cancer Institute (NCI)RekrutteringTilbagevendende blærekræft | Stadie III blærekræft | Stadie IV blærekræft | Ureterkræft | Distal urinrørskræft | Proksimal urinrørskræft | Tilbagevendende urinrørskræft | Stadie III Urethral Cancer | Stadie IV UrethralkræftForenede Stater
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)AfsluttetPlanocellulært karcinom i hoved og halsForenede Stater
-
M.D. Anderson Cancer CenterBoehringer IngelheimAfsluttetLungekræftForenede Stater